All patients
subjects at risk
chloroquine and derivatives in COVID 19 outpatients - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 1.15 [0.02; 58.61]
COMIHY, 2020 1.00 [0.02; 57.31]
COPE – Coalition V, 2022 1.56 [0.39; 6.24]
COVID-PEP Severity (Skipper), 2020 1.01 [0.06; 16.28]
PATCH Cohort 1 (Amaravadi), 2021 0.86 [0.02; 46.71]
1.32 [0.44 ; 3.93 ] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, COMIHY, 2020, COPE – Coalition V, 2022, COVID-PEP Severity (Skipper), 2020, PATCH Cohort 1 (Amaravadi), 2021 5 0% 2,197 moderate serious hospitalization or deathdetailed results ALBERTA HOPE-Covid19, 2021 2.73 [0.14; 52.87]
2.73 [0.14 ; 52.87 ] ALBERTA HOPE-Covid19, 2021 1 0% 148 NA not evaluable clinical deteriorationdetailed results PATCH Cohort 1 (Amaravadi), 2021 0.51 [0.07; 3.68]
0.51 [0.07 ; 3.68 ] PATCH Cohort 1 (Amaravadi), 2021 1 0% 28 NA not evaluable clinical improvementdetailed results COVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11]
1.36 [0.87 ; 2.11 ] COVID-PEP Severity (Skipper), 2020 1 0% 395 NA not evaluable clinical improvement (14-day)detailed results COVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11]
1.36 [0.87 ; 2.11 ] COVID-PEP Severity (Skipper), 2020 1 0% 395 NA not evaluable hospitalizationdetailed results BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 0.75 [0.32; 1.76]
COPE – Coalition V, 2022 0.77 [0.52; 1.13]
PATCH Cohort 1 (Amaravadi), 2021 1.79 [0.06; 57.93]
0.77 [0.55 ; 1.10 ] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, COPE – Coalition V, 2022, PATCH Cohort 1 (Amaravadi), 2021 3 0% 1,694 moderate not evaluable mechanical ventilationdetailed results COPE – Coalition V, 2022 1.32 [0.46; 3.79]
1.32 [0.46 ; 3.79 ] COPE – Coalition V, 2022 1 0% 1,369 NA not evaluable viral clearance detailed results Q-PROTECT -HCQ alone, 2020 0.88 [0.53; 1.45]
0.88 [0.53 ; 1.45 ] Q-PROTECT -HCQ alone, 2020 1 0% 289 NA not evaluable viral clearance by day 14detailed results Q-PROTECT -HCQ alone, 2020 0.88 [0.53; 1.45]
0.88 [0.53 ; 1.45 ] Q-PROTECT -HCQ alone, 2020 1 0% 289 NA not evaluable viral clearance by day 7detailed results Q-PROTECT -HCQ alone, 2020 1.05 [0.53; 2.09]
1.05 [0.53 ; 2.09 ] Q-PROTECT -HCQ alone, 2020 1 0% 296 NA not evaluable ICU admissiondetailed results COPE – Coalition V, 2022 0.84 [0.43; 1.63]
0.84 [0.43 ; 1.63 ] COPE – Coalition V, 2022 1 0% 1,369 NA not evaluable adverse eventsdetailed results Out of scale BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 178.20 [73.71; 430.85]
COVID-PEP Severity (Skipper), 2020 2.75 [1.80; 4.21]
21.73 [0.36 ; 1295.07 ] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, COVID-PEP Severity (Skipper), 2020 2 99% 776 moderate not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-19 02:13 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 97
- treatments: 508,656,657,832
- roots T: 290
